{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:44:46Z","timestamp":1787903086413,"version":"build-2784847793"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,6,12]]},"DOI":"10.18632\/oncotarget.28454","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T08:38:07Z","timestamp":1686559087000},"page":"597-611","source":"Crossref","is-referenced-by-count":4,"title":["LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair"],"prefix":"10.18632","volume":"14","author":[{"given":"Jianli","family":"Zhou","sequence":"first","affiliation":[{"name":"Lantern Pharma Inc., Plano, TX 75024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Sturtevant","sequence":"additional","affiliation":[{"name":"Lantern Pharma Inc., Plano, TX 75024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie","family":"Love","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University, Durham, NC 27708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Lantern Pharma Inc., Plano, TX 75024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Biyani","sequence":"additional","affiliation":[{"name":"Lantern Pharma Inc., Plano, TX 75024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Kathad","sequence":"additional","affiliation":[{"name":"Lantern Pharma Inc., Plano, TX 75024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thacker","sequence":"additional","affiliation":[{"name":"Data Driven Bioscience, Durham, NC 27707, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dave","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University, Durham, NC 27708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Lantern Pharma Inc., Plano, TX 75024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of Non-Hodgkin\u2019s Lymphoma","volume":"9","author":"Rawla","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/jpm12030376","article-title":"Relapsed\/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors","volume":"1","author":"Karmali","year":"2022","journal-title":"J Pers Med"},{"key":"3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.46883\/2022.25920963","article-title":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma: \u201cDazed and Confused\u201d","volume":"3","author":"Lunning","year":"2022","journal-title":"Oncology (Williston Park)"},{"key":"4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349509","article-title":"New Directions for Mantle Cell Lymphoma in 2022","volume":"4","author":"Cheah","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ajh.26068","article-title":"First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study","volume":"9","author":"Marouf","year":"2021","journal-title":"Am J Hematol"},{"key":"6","doi-asserted-by":"publisher","first-page":"102090","DOI":"10.1016\/j.ctrv.2020.102090","article-title":"Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences","volume":"9","author":"Bertoni","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"7","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1093\/nar\/gkv160","article-title":"Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation","volume":"4","author":"Mansour","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41467-018-07729-2","article-title":"ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks","volume":"1","author":"Ponstingl","year":"2019","journal-title":"Nat Commun"},{"key":"9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3978\/j.issn.2218-676X.2013.04.02","article-title":"DNA double strand break repair via non-homologous end-joining","volume":"2","author":"Chen","year":"2013","journal-title":"Transl Cancer Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/cr.2008.6","article-title":"Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects","volume":"1","author":"Mullenders","year":"2008","journal-title":"Cell Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00018-009-8736-z","article-title":"DNA repair in mammalian cells: Base excision repair: the long and short of it","volume":"6","author":"Leiros","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cr.2007.115","article-title":"Mechanisms and functions of DNA mismatch repair","volume":"1","author":"Li","year":"2008","journal-title":"Cell Res"},{"key":"13","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2020","journal-title":"Blood Adv"},{"key":"14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3324\/haematol.2011.049270","article-title":"ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression","volume":"9","author":"Mauro","year":"2012","journal-title":"Haematologica"},{"key":"15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","article-title":"LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL","volume":"3","author":"Bilbao-Cortes","year":"2019","journal-title":"Cancer Cell"},{"key":"16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1517\/13543776.17.9.1061","article-title":"Alkylating agents and cancer therapy","volume":"1","author":"Kaur","year":"2007","journal-title":"Expert Opin Ther Pat"},{"key":"17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1631\/jzus.B2000344","article-title":"DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy","volume":"2","author":"Pei","year":"2021","journal-title":"J Zhejiang Univ Sci B"},{"key":"18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CM9.0000000000001294","article-title":"R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms","volume":"13","author":"Li","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3892\/or.2022.8325","article-title":"Bendamustine: A review of pharmacology, clinical use and immunological effects (Review)","volume":"4","author":"Babic","year":"2022","journal-title":"Oncol Rep"},{"key":"20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/s1568-7864(02)00166-0","article-title":"Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways","volume":"1","author":"Hoeijmakers","year":"2002","journal-title":"DNA Repair (Amst)"},{"key":"21","doi-asserted-by":"publisher","first-page":"5604","DOI":"10.1158\/1078-0432.CCR-04-0442","article-title":"Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells","volume":"1","author":"Larsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"1033395","DOI":"10.3389\/fddsv.2022.1033395","article-title":"Artificial intelligence platform, RADR\u00ae, aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid Tumors","volume":"2","author":"Bhatia","year":"2022","journal-title":"Frontiers Drug Discov"},{"key":"23","doi-asserted-by":"publisher","first-page":"e40342","DOI":"10.1371\/journal.pone.0040342","article-title":"Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine","volume":"7","author":"Yen","year":"2012","journal-title":"PLoS One"},{"key":"24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.dnarep.2015.10.003","article-title":"Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links","volume":"3","author":"Patrick","year":"2015","journal-title":"DNA Repair (Amst)"},{"key":"25","first-page":"2817","article-title":"Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin","volume":"9","author":"Larsen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"48","author":"Murray","year":"2012","journal-title":"Nature"},{"key":"27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","article-title":"Toil enables reproducible, open source, big biomedical data analyses","volume":"3","author":"Craft","year":"2017","journal-title":"Nat Biotechnol"},{"key":"28","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A Landscape of Pharmacogenomic Interactions in Cancer","volume":"16","author":"van Dyk","year":"2016","journal-title":"Cell"},{"key":"29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/1535-7163.MCT-09-0872","article-title":"ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors","volume":"9","author":"Lees-Miller","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41375-021-01347-6","article-title":"Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma","volume":"3","author":"Mazzara","year":"2022","journal-title":"Leukemia"},{"key":"31","doi-asserted-by":"publisher","first-page":"18062","DOI":"10.1038\/s41598-019-54407-4","article-title":"Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model","volume":"9","author":"St\u00fchmer","year":"2019","journal-title":"Sci Rep"},{"key":"32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-015-0132-6","article-title":"YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway","volume":"8","author":"Tyner","year":"2015","journal-title":"J Hematol Oncol"},{"key":"33","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","article-title":"CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set","volume":"7","author":"Pommier","year":"2012","journal-title":"Cancer Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cellsand","volume":"2","author":"Yi","year":"2008","journal-title":"Leukemia"},{"key":"35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/bloodadvances.2020001665","article-title":"Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2","volume":"5","author":"Xia","year":"2021","journal-title":"Blood Adv"},{"key":"36","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1093\/nar\/gkz1118","article-title":"STRIDE-a fluorescence method for direct, specificdetection of individual single- or double-strand DNA breaks in fixed cells","volume":"4","author":"Dobrucki","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"103433","DOI":"10.1016\/j.dnarep.2022.103433","article-title":"The mutational impact of Illudin S on human cells","volume":"12","author":"Mar\u00e9chal","year":"2023","journal-title":"DNA Repair (Amst)"},{"key":"38","doi-asserted-by":"publisher","first-page":"39584","DOI":"10.1074\/jbc.M400015200","article-title":"ATM-dependent CHK2 activation induced by anticancer agent, irofulven","volume":"27","author":"Wang","year":"2004","journal-title":"J Biol Chem"},{"key":"39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/mutage\/6.6.449","article-title":"The repair of 4-nitroquinoline-1-oxide induced DNA adducts in hypersensitive Chinese hamster mutants: lack of repair of UV induced (6-4) photoproduct correlates with reduced repair of adducts at the N2 of guanosine","volume":"6","author":"Waters","year":"1991","journal-title":"Mutagenesis"},{"key":"40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0027-5107(82)90276-7","article-title":"A CHO-cell strain having hypersensitivity to mutagens, a defect in DNA strand-break repair, and an extraordinary baseline frequency of sister-chromatid exchange","volume":"9","author":"Minkler","year":"1982","journal-title":"Mutat Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.chembiol.2013.12.014","article-title":"A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum","volume":"2","author":"Coin","year":"2014","journal-title":"Chem Biol"},{"key":"42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/leu.2017.182","article-title":"Nucleotide excision repair is a potential therapeutic target in multiple myeloma","volume":"3","author":"Tai","year":"2018","journal-title":"Leukemia"},{"key":"43","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hon.2933","article-title":"The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma","volume":"3","author":"Zhou","year":"2021","journal-title":"Hematol Oncol"},{"key":"44","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.3390\/cancers13215328","article-title":"PARP Inhibitors and Haematological Malignancies-Friend or Foe?","volume":"1","author":"Lincz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.v99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"9","author":"Campo","year":"2002","journal-title":"Blood"},{"key":"46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/1541-7786.MCR-16-0468","article-title":"IGH\/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors","volume":"1","author":"Piwocka","year":"2017","journal-title":"Mol Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T08:38:14Z","timestamp":1686559094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,6,12]]}},"alternative-id":["28454"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28454","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}